

3 March 2025

Versarien plc

("Versarien" or the "Company")

Completion of Sale of Korean Assets

Further to the Company's announcement on 30 December 2024, Versarien (AIM: VRS), the advanced materials engineering group, provides an update on the sale of its Korean plant and equipment to MCK Tech Co. Ltd ("MCK Tech").

Versarien has now received the final payment due from MCK Tech of £92,000, plus accrued interest, and therefore the sale of its Korean plant and equipment has completed, with title to the assets transferred to MCK Tech. In total, Versarien has now received £611,000 including the interest payment, after a £6,000 warranty deduction, from MCK Tech for its Korean plant and equipment.

As announced by Versarien on 11 March 2024, in line with the Company's strategy to monetise intellectual property through licensing, Versarien granted an exclusive licence to MCK Tech (the "Licence"), for an initial period of five years, to use five patents owned by the Company in their business in Korea. These five patent licences are in addition to 14 patents the Company licences to Graphene Lab Co Ltd. MCK Tech will pay Versarien an amount equal to 4.5% of the total sales revenue earned from products manufactured using the IP. If the sales revenue derived from the IP is less than £250,000 over the first two years of the Licence, the Licence will terminate and MCK Tech will pay Versarien £40,000 for use of the IP.

For further information please contact:

Versarien
Stephen Hodge, Chief Executive Officer
Chris Leigh, Chief Financial Officer

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)
Matthew Johnson, Adam Cowl

+44 (0)20 3470 0470

IFC Advisory Limited (Financial PR and Investor Relations)
Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

About Versarien:

The strategy of Versarien plc (AIM:VRS) is to be a development led advanced materials company focussed on specific sectors that will lead to a manufacturing-light and licensing model.

For further information please see: <http://www.versarien.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DISEAXAPAAESEFA